Details

Autor(en) / Beteiligte

• Rosenwald, Andreas
• Wright, George
• Chan, Wing C
• Connors, Joseph M
• Campo, Elias
• Fisher, Richard I
• Gascoyne, Randy D
• Muller-Hermelink, H. Konrad
• Smeland, Erlend B
• Giltnane, Jena M
• Hurt, Elaine M
• Zhao, Hong
• Averett, Lauren
• Yang, Liming
• Wilson, Wyndham H
• Jaffe, Elaine S
• Simon, Richard
• Klausner, Richard D
• Powell, John
• Duffey, Patricia L
• Longo, Dan L
• Greiner, Timothy C
• Weisenburger, Dennis D
• Sanger, Warren G
• Dave, Bhavana J
• Lynch, James C
• Vose, Julie
• Armitage, James O
• Montserrat, Emilio
• López-Guillermo, Armando
• Grogan, Thomas M
• Miller, Thomas P
• LeBlanc, Michel
• Ott, German
• Kvaloy, Stein
• Delabie, Jan
• Holte, Harald
• Krajci, Peter
• Stokke, Trond
• Staudt, Louis M

Titel

The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma

Ist Teil von

• The New England journal of medicine, 2002-06, Vol.346 (25), p.1937-1947

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2002

Quelle

MEDLINE

Beschreibungen/Notizen

• In a large group of diffuse large-B-cell lymphomas, DNA microarrays identified three patterns of gene expression that were correlated with the likelihood of survival after chemotherapy. Individual genes within these patterns formed molecular signatures that had an even stronger correlation with survival after chemotherapy. The predictive power of the molecular signatures was independent of the international prognostic index. In diffuse large-B-cell lymphomas, three patterns correlated with the likelihood of survival. Diffuse large-B-cell lymphoma, the most common type of lymphoma in adults, can be cured by anthracycline-based chemotherapy in only 35 to 40 percent of patients. 1 The multiple unsuccessful attempts to increase this rate 2 suggest that diffuse large-B-cell lymphoma actually comprises several diseases that differ in responsiveness to chemotherapy. Support for this idea comes from a study of gene-expression profiles, which identified two subgroups of diffuse large-B-cell lymphoma that had different outcomes after multiagent chemotherapy. 3 The germinal-center B-cell–like subgroup expressed genes characteristic of normal germinal-center B cells and were associated with a good outcome, whereas the activated B-cell–like subgroup expressed genes . . .